CRISPR Therapeutics AG (CRSP)
54.64
+0.91
(+1.69%)
USD |
NASDAQ |
Apr 26, 10:41
CRISPR Therapeutics Cash from Investing (Quarterly): -81.45M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -81.45M |
| September 30, 2023 | 121.35M |
| June 30, 2023 | 216.92M |
| March 31, 2023 | 117.83M |
| December 31, 2022 | -175.53M |
| September 30, 2022 | 87.46M |
| June 30, 2022 | -56.07M |
| March 31, 2022 | -114.52M |
| December 31, 2021 | -8.716M |
| September 30, 2021 | -565.18M |
| June 30, 2021 | -293.64M |
| March 31, 2021 | -167.90M |
| December 31, 2020 | -204.24M |
| September 30, 2020 | -330.33M |
| June 30, 2020 | -3.605M |
| March 31, 2020 | -2.991M |
| Date | Value |
|---|---|
| December 31, 2019 | 7.057M |
| September 30, 2019 | -2.461M |
| June 30, 2019 | -2.174M |
| March 31, 2019 | -1.097M |
| December 31, 2018 | -1.00M |
| September 30, 2018 | -0.695M |
| June 30, 2018 | -0.523M |
| March 31, 2018 | -0.555M |
| December 31, 2017 | -0.205M |
| September 30, 2017 | -3.494M |
| June 30, 2017 | -1.33M |
| March 31, 2017 | -3.285M |
| December 31, 2016 | 14.77M |
| September 30, 2016 | -1.509M |
| June 30, 2016 | -1.047M |
| March 31, 2016 | 19.67M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-565.18M
Minimum
Sep 2021
216.92M
Maximum
Jun 2023
-76.75M
Average
-8.716M
Median
Dec 2021
Cash from Investing (Quarterly) Benchmarks
| Vertex Pharmaceuticals Inc | -886.50M |
| Intellia Therapeutics Inc | 45.94M |
| Novartis AG | -899.00M |
| Verve Therapeutics Inc | -8.893M |
| AC Immune SA | 25.14M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -96.07M |
| Cash from Financing (Quarterly) | 38.94M |
| Free Cash Flow | -272.34M |
| Free Cash Flow Per Share (Quarterly) | -1.215 |
| Free Cash Flow to Equity (Quarterly) | -96.81M |
| Free Cash Flow to Firm (Quarterly) | -96.81M |
| Free Cash Flow Yield | -6.29% |